Cited by 83Cannabis and Cannabinoid ResearchRegulation of Appetite and ObesityPharmacology and Obesity Treatment

The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake

Open access
Thornton-Jones, Zoë D., Kennett, Guy A., Benwell, Karen R., Revell, Dean F., Misra, Anil, Sellwood, Daniel M., Vickers, Steven P., Clifton, Peter G.·2006·Pharmacology Biochemistry and Behavior

Abstract

The cannabinoid CB1 receptor inverse agonist rimonabant induces hypophagia and body weight loss. Reduced body weight may potentially be due to decreased food intake or to direct metabolic effects of drug administration on energy expenditure. This study uses a paired-feeding protocol to quantify the contributions of energy intake to rimonabant-induced body weight loss. Diet-induced obese (DIO) rats were dosed with rimonabant (3, 10 mg/kg PO once daily) and matched with pair-fed controls. Food intake and body weight were measured daily. Blood samples and adipose tissue were collected on day 15 for measurement of plasma adiponectin and adiponectin mRNA levels. DIO rats treated with rimonabant and pair-fed controls showed very similar changes in body weight. Although tolerance developed to the anorectic effect of rimonabant, total food intake was significantly decreased over the 14-day study period and fully accounted for the observed reductions in body weight. Adiponectin mRNA and plasma adiponectin were elevated in vehicle-treated chow-fed animals compared to obese controls, and did not differ between rimonabant-treated and pair-fed animals. The similarities between rimonabant-treated and pair-fed animals in body weight loss and the absence of differences in measures of adiponectin activity between drug-treated and pair-fed animals suggest that the outcomes of this experiment were solely mediated by the drug-induced reduction in food intake.

Integrity signals

Registry

Crossref · 10.1016/j.pbb.2006.06.001

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intraperitoneal administration of rimonabant reduces food intake and induces neuronal activation in hypothalamic nuclei involved in food intake regulation, such as the paraventricular nucleus.

    “For instance, intraperitoneal administration of rimonabant (an antagonist for the cannabinoid receptor CB 1 ) reduces food intake (Thornton-Jones et al., 2006) and induces neuronal activation in several hypothalamic nuclei involved in food intake regulation, such as the paraventricular nucleus (Verty et al., 2009).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thornton-Jones, Z. D., Kennett, G. A., Benwell, K. R., Revell, D. F., Misra, A., Sellwood, D. M., Vickers, S. P., & Clifton, P. G.
Affiliations
  • University of Sussex (GB)
  • Vernalis (R&D) Limited (United Kingdom) (GB)
Corresponding author
Clifton, Peter G.
Venue
Pharmacology Biochemistry and Behavior
Publisher
Elsevier BV
Published
2006-06
Volume
84
Issue
2
Pages
353-359
ISSN
0091-3057 (ISSN-L)
OpenAlex
W2058364253
Cited by
83
References
40
Citations by year
2025: 3 · 2024: 1 · 2023: 1 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 5
FWCI
6.44
Type
journal article
Language
en
Open access
Locations
  • Pharmacology Biochemistry and Behavior (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
Medical Research Council
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
rimonabant, diet-induced obesity, weight loss, dietary intake, hypophagia, adiponectin, pair feeding, cannabinoid receptor antagonists, energy expenditure
MeSH terms
Rimonabant, Animals, Body Weight, Dietary Fats, Eating, Male, Obesity, Piperidines, Pyrazoles, Rats, Sprague-Dawley, Receptor, Cannabinoid, CB1, Rats, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review